by Maria Zannes | Sep 29, 2025 | Press Releases
SAN ANTONIO, TX – September 29, 2025 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a public offering of securities as...
by Maria Zannes | Sep 26, 2025 | Press Releases
Noninvasive diagnostic test again leads to detecting Stage 1A lung cancer SAN ANTONIO, TX – September 26, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases,...
by Maria Zannes | Sep 17, 2025 | Press Releases
SAN ANTONIO, TX – September 17, 2025 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-30 reverse split of its...
by Maria Zannes | Sep 9, 2025 | Press Releases
bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO, TX – September 9, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a...
by Maria Zannes | Sep 3, 2025 | Press Releases
Noninvasive diagnostic can help federal medical system address veterans at higher risk for developing lung cancer SAN ANTONIO, TX – September 3, 2025 – U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Technologies’...
